|
Genentech Gets Untitled Letter for Claims in Oncology Drug Promo
The FDA has issued an untitled letter to Genentech for educational aids aimed at healthcare professionals that overstate the efficacy and minimize the risks of its cancer drug Tarceva.
This article is viewable by subscribers only. To view this article, please select an option below.
|
|
Subscribe
Archives